Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: "Spectrum Pharmaceuticals, Inc." (SPPI) Report Updated: Feb 01, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"Spectrum Pharmaceuticals, Inc." (SPPI)

Rating: Sell Volatility: Moderate
Total Grade: D Industry: Biotechnology
Competitors: SPHS, ANAC, REPH, LGND

Stock Analysis

Rating: Monthly View

February March April May June July August September October November December January

Rating: Weekly View

This Week: D down downgrade
Last Week: C same no change
Two Weeks Ago: C up no change
service keys

"Spectrum Pharmaceuticals, Inc."© quotemedia

Company Profile

Spectrum Pharmaceuticals, Inc., a biotechnology company, engages in acquiring, developing, and commercializing prescription drug products primarily in the areas of hematology and oncology. It offers ZEVALIN, a prescribed form of cancer therapy which combines a source of radiation with an antibody; and FUSILEV for patients with osteosarcoma after high-dose methotrexate therapy, as well as to diminish the toxicity and counteract the effects of impaired methotrexate elimination or inadvertent overdose of folic acid antagonists. The company also develops apaziquone that is under Phase 3 clinical trials for non-muscle invasive bladder cancer; and belinostat, which is under Phase 2 registrational trial for relapsed or refractory peripheral T-cell lymphoma. In addition, it develops ozarelix that is under randomized phase 2 clinical trial in prostate cancer patients; ortataxel, which has completed Phase 2 studies in solid tumor patients; lucanthone an orally administered small-molecule that has completed preclinical tests; SPI-1620, which has completed Phase 1 study is a peptide agonist of endothelin B receptors; and RenaZorb, a lanthanum-based nanoparticle phosphate binding agent; and SPI-2012, a drug for the treatment of chemotherapy induced neutropenia. It has strategic collaborations with Allergan, Inc., Nippon Kayaku Co. Ltd., and Handok Pharmaceuticals Co. Ltd. for the development and commercialization of apaziquone; with TopoTarget A/S for the development and commercialization of belinostat; and a co-development and commercialization agreement with Hanmi Pharmaceutical Company for SPI-2012. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is based in Henderson, Nevada.

Recent News: "Spectrum Pharmaceuticals, Inc."